.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
MASAI RCT: 12% reduction in interval cancer rate using Transpara
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
Transpara Announces New FDA Clearance at RSNA 2024
.png)
Transpara Announces New FDA Clearance at RSNA 2024
SPM Showcases Innovative FDA Cleared Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance
December 02, 2024
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
.png)
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
Pieter Kroese appointed as the Chief Executive Officer of ScreenPoint Medical, effective April 25, 2024.
April 05, 2024
ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection
.png)
ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection
Transpara implemented for clinical use by key thought leaders in radiology and breast imaging.
March 12, 2024